Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 29;18(2):1886560.
doi: 10.1080/21645515.2021.1886560. Epub 2021 May 19.

Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases

Tharmala Tharmalingam  1 , Xiaobing Han  1   2 , Ashley Wozniak  1 , Laura Saward  1   3
Affiliations
Review

Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases

Tharmala Tharmalingam et al. Hum Vaccin Immunother. .

Abstract

Passive immunization with polyclonal hyper immunoglobulin (HIG) therapy represents a proven strategy by transferring immunoglobulins to patients to confer immediate protection against a range of pathogens including infectious agents and toxins. Distinct from active immunization, the protection is passive and the immunoglobulins will clear from the system; therefore, administration of an effective dose must be maintained for prophylaxis or treatment until a natural adaptive immune response is mounted or the pathogen/agent is cleared. The current review provides an overview of this technology, key considerations to address different pathogens, and suggested improvements. The review will reflect on key learnings from development of HIGs in the response to public health threats due to Zika, influenza, and severe acute respiratory syndrome coronavirus 2.

Keywords: immunoglobulin; infectious disease; passive immunotherapy; pathogen.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Baxter D. Active and passive immunity, vaccine types, excipients and licensing. Occup Med (Lond). 2007;57(8):1–20. doi:10.1093/occmed/kqm110. - DOI - PubMed
    1. Pauna AM, Luca AC, Azoicăi D.. Influenza vaccination. Advantages and disadvantages. SEA-Pract Appl Sci. 2019;7(20).131–6.
    1. Verma P, Thakur A, Deshmukh K, Jha A, Verma S. Routes of drug administration. Int J Pharm Stud Res. 2010;1:54–59.
    1. Shibata Y, Baba M, Kuniyuki M. Studies on the retention of passively transferred antibodies in man. II. Antibody activity in the blood after intravenous or intramuscular administration of anti-HBs human immunoglobulin. Vox Sang. 1983;45(1):77–82. doi:10.1111/j.1423-0410.1983.tb04126.x. - DOI - PubMed
    1. Reyneveld GI, Savelkoul HFJ, Parmentier HK. Current understanding of natural antibodies and exploring the possibilities of modulation using veterinary models. A review. Front Immunol. 2020;11(2139):2139. doi:10.3389/fimmu.2020.02139. - DOI - PMC - PubMed

Publication types